AMBER RARDIN: Open Payments
NPI 1043838238 · WILSON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$674 in 43 payments from 11 companies in 2025. Trend: 2023 $792 · 2024 $668 · 2025 $674
Food & beverage: $674
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $166 |
| ABBVIE INC. | 13 | $139 |
| Neurocrine BioSciences, Inc. | 6 | $122 |
| Janssen Pharmaceuticals, Inc | 2 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: REXULTI, VRAYLAR, INGREZZA, INVEGA SUSTENNA, CAPLYTA, Jornay PM, COBENFY, Xelstrym.
Industry payments across NC — which companies pay providers there.
